Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
Background Next generation, higher valency pneumococcal conjugate vaccines (PCVs) are assessed and licensed by comparing the immune response across serotypes shared with the PCVs that are standard of care for prevention of pneumococcal disease.Methods Using a previously qualified method we predicted...
Saved in:
Main Authors: | Josiah Ryman, Jeffrey R. Sachs, Natalie Banniettis, Thomas Weiss, Maurice Ahsman, Ka Lai Yee, Jessica Weaver |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2335323 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
by: Josiah Ryman, et al.
Published: (2024-12-01) -
Epidemiology of Streptococcus pneumoniae serotypes in children before and after pneumococcal vaccination
by: I. N. Protasova, et al.
Published: (2021-12-01) -
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01) -
Predicting the Epidemiological Effects in the United Kingdom of Moving from PCV13 to PCV15 in the Routine Pediatric 1 + 1 Vaccination Schedule
by: Rachel J. Oidtman, et al.
Published: (2025-06-01) -
SEROTYPE CHARACTERISTIC OF PNEUMOCOCCI ISOLATED FROM PATIENTS WITH PNEUMOCOCCAL MENINGITIS
by: I. S. Koroleva, et al.
Published: (2012-07-01)